Ignite Creation Date:
2024-05-06 @ 7:04 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05880355
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-10-02
First Post:
2023-05-04
Brief Title:
Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation
Sponsor:
University of Virginia
Organization:
University of Virginia
Study Overview
Official Title:
Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Subjects with urgently reperfused type I myocardial infarction MI will be recruited and randomized to receive either placebo or the oral inflammasome NLRP3 inhibitor dapansutrile The primarily outcome measure will be carotid plaque volume change over 6 months secondary outcome measures will be plaque inflammatory activity and coronary microvascular function
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None